Search results
Results from the WOW.Com Content Network
Sometimes the term "LNP" describes all lipid-based nanoparticles. In specific applications, LNPs describe a specific type of lipid-based nanoparticle, such as the LNPs used for the mRNA vaccine. [1] [2] [3] Using LNPs for drug delivery was first approved in 2018 for the siRNA drug Onpattro. [4]
Selective organ targeting (SORT) is a novel approach in the field of targeted drug delivery that systematically engineers multiple classes of lipid nanoparticles (LNPs) to enable targeted delivery of therapeutics to specific organs in the body.
Pieter Rutter Cullis FRS FRSC OBC OC is a Canadian physicist and biochemist known for his contributions to the field of lipid nanoparticles (LNP). [1] Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines.
Furthermore, effective intracellular delivery could expand the repertoire of usable protein drugs as most current protein-based therapeutics hit extracellular targets and this is a frontier of current research efforts. [27] Delivery of purified proteins into cells began as early as the 1960s.
Learn about delivery delays. Messages are often delivered right way though very rarely there may be a delay in transit. This is usually due to problems on the mail server, heavy internet traffic, or routing problems. Unfortunately, other than waiting, you won't be able to determine if the message is delayed or undeliverable.
The PEGylated lipid nanoparticle drug delivery (LNP) system of the mRNA vaccine known as mRNA-1273 has been the subject of ongoing patent litigation with Arbutus Biopharma, from whom Moderna had previously licensed LNP technology. [25] [26] On 4 September 2020, Nature Biotechnology reported that Moderna had lost a key challenge in the ongoing ...
Lipid nanoparticles (LNPs) are being considered for delivering siRNA to silence AR. The most effective LNP to be found in vivo contains an ionizable cationic lipid 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA). [4] Serum prostate specific antigen (PSA) is an antigen that is present in high levels in prostate cancer.
Acuitas Therapeutics Inc. is a Canadian biotechnology company based in Vancouver, British Columbia.The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19.